On 4th November, the UK's Medicines and Healthcare products Regulatory Agency approved the first antiviral pill, molnupiravir, to be used in response to the coronavirus pandemic. This article outlines how the new pill works, how it will be distributed, and any potential side effects.

Please feel free to download and share this information with colleagues and friends who may also find it useful. Alternatively, contact us directly if you wish to discuss this further.

0161 300 2930 Blackfriars Group